Submit Manuscript  

Article Details


Molecular Topology and Other Promiscuity Determinants as Predictors of Therapeutic Class - A Theoretical Framework to Guide Drug Repositioning?

[ Vol. 18 , Issue. 13 ]

Author(s):

Juan F. Morales, Lucas N. Alberca, Sara Chuguransky, Mauricio E. Di Ianni, Alan Talevi* and Maria E. Ruiz   Pages 1110 - 1122 ( 13 )

Abstract:


Much interest has been paid in the last decade on molecular predictors of promiscuity, including molecular weight, log P, molecular complexity, acidity constant and molecular topology, with correlations between promiscuity and those descriptors seemingly being context-dependent. It has been observed that certain therapeutic categories (e.g. mood disorders therapies) display a tendency to include multi-target agents (i.e. selective non-selectivity). Numerous QSAR models based on topological descriptors suggest that the topology of a given drug could be used to infer its therapeutic applications. Here, we have used descriptive statistics to explore the distribution of molecular topology descriptors and other promiscuity predictors across different therapeutic categories. Working with the publicly available ChEMBL database and 14 molecular descriptors, both hierarchical and non-hierchical clustering methods were applied to the descriptors mean values of the therapeutic categories after the refinement of the database (770 drugs grouped into 34 therapeutic categories). On the other hand, another publicly available database (repoDB) was used to retrieve cases of clinically-approved drug repositioning examples that could be classified into the therapeutic categories considered by the aforementioned clusters (111 cases), and the correspondence between the two studies was evaluated. Interestingly, a 3- cluster hierarchical clustering scheme based on only 14 molecular descriptors linked to promiscuity seem to explain up to 82.9% of approved cases of drug repurposing retrieved of repoDB. Therapeutic categories seem to display distinctive molecular patterns, which could be used as a basis for drug screening and drug design campaigns, and to unveil drug repurposing opportunities between particular therapeutic categories.

Keywords:

Molecular Topology, Promiscuity, Promiscuity determinants, Drug repurposing, Drug repositioning, Therapeutic indication shift, Indication expansion, Drug rescue, Systematic drug repositioning, Clustering.

Affiliation:

Departamento de Ciencias Biologicas, Laboratorio de Investigacion y Desarrollo de Bioactivos (LIDeB), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Calles 47 y 115 (B1900AJI) La Plata, Buenos Aires, Departamento de Ciencias Biologicas, Laboratorio de Investigacion y Desarrollo de Bioactivos (LIDeB), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Calles 47 y 115 (B1900AJI) La Plata, Buenos Aires, Departamento de Ciencias Biologicas, Laboratorio de Investigacion y Desarrollo de Bioactivos (LIDeB), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Calles 47 y 115 (B1900AJI) La Plata, Buenos Aires, Departamento de Ciencias Biologicas, Laboratorio de Investigacion y Desarrollo de Bioactivos (LIDeB), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Calles 47 y 115 (B1900AJI) La Plata, Buenos Aires, Departamento de Ciencias Biologicas, Laboratorio de Investigacion y Desarrollo de Bioactivos (LIDeB), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Calles 47 y 115 (B1900AJI) La Plata, Buenos Aires, Departamento de Ciencias Biologicas, Laboratorio de Investigacion y Desarrollo de Bioactivos (LIDeB), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Calles 47 y 115 (B1900AJI) La Plata, Buenos Aires

Graphical Abstract:



Read Full-Text article